Defining the role of peritoneal dialysis in management of congestive heart failure

References

• Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–1133.
   PubMed Web of Science ®Google Scholar
• Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000-2010. NCHS Data Brief. 2012;108:1–8.
   Google Scholar
• Centers for Disease Control. Heart Failure Fact Sheet. [cited 2019 Apr 29]. Available from: http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm
   Google Scholar
• Grady KL, Dracup K, Kennedy G, et al. Team management of patients with heart failure: a statement for healthcare professionals from the cardiovascular nursing council of the American Heart Association. Circulation. 2000;102:2443–2456.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–619.
   PubMed Web of Science ®Google Scholar
• Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.
   PubMedGoogle Scholar
• Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 2013;77:2209–2217.
   PubMedGoogle Scholar
• Keates AK, Mocumbi AO, Ntsekhe M, et al. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol. 2017;14:273–293.
   PubMed Web of Science ®Google Scholar
• Damasceno A, Cotter G, Dzudie A, et al. Heart failure in sub‐saharan Africa: time for action. J Am Coll Cardiol. 2007;50:1688–1693.
   PubMed Web of Science ®Google Scholar
• Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–1443.
   PubMed Web of Science ®Google Scholar
• Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial.J. Am Coll Cardiol. 2007;50:741–747.
   PubMed Web of Science ®Google Scholar
• Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the heart failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:433–443.
   PubMed Web of Science ®Google Scholar
• Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. PharmacoEconomics. 2008;26:447–462.
   PubMed Web of Science ®Google Scholar
• Stewart S, Wilkinson D, Hansen C, et al. Predominance of heart failure in the heart of soweto study cohort: emerging challenges for urban African communities. Circulation. 2008;118:2360–2367.
   PubMed Web of Science ®Google Scholar
• Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace. 2011;13(Suppl 2):ii13–7.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;128:1810–1852.
   PubMed Web of Science ®Google Scholar
• Kengne AP, Dzudie A, Sobngwi E. Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes. Vasc Health Risk Manag. 2008;4:123–130.
   PubMedGoogle Scholar
• Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013;34:835–843.
   PubMed Web of Science ®Google Scholar
• Palazzuoli A, Lombardi C, Ruocco G, et al. Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact? Eur Heart J Acute Cardiovasc Care. 2016;5:534–548.
   PubMed Web of Science ®Google Scholar
• Volpe M, Tritto C, DeLuca N, et al. Abnormalities of sodium handling and of cardiovascular adaptations during high salt diet in patients with mild heart failure. Circulation. 1993;88:1620–1627.
   PubMed Web of Science ®Google Scholar
• Farmakis D, Bistola V, Karavidas A, et al. Practical considerations on the introduction of sacubitril/valsartan in clinical practice: current evidence and early experience. Int J Cardiol. 2016;223:781–784.
   PubMed Web of Science ®Google Scholar
• Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol. 2019;ii: CJN.09630818. Epub ahead of print. DOI:10.2215/CJN.09630818
   Web of Science ®Google Scholar
• Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med. 1983;102:450–458.
   PubMed Web of Science ®Google Scholar
• Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132–143.
   PubMed Web of Science ®Google Scholar
• Ter Maaten JM, Valente MA, Damman K, et al. Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Card. 2015;12:184–192.
   PubMed Web of Science ®Google Scholar
• Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35:1284–1293.
   PubMed Web of Science ®Google Scholar
• Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7:261–270.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Cerbin LP, Armstrong PW, et al. Body weight change during and after hospitalization for acute heart failure: patient characteristics, markers of congestion, and outcomes: findings from the ASCEND-HF trial. JACC Heart Fail. 2017;5:1–13.
   PubMed Web of Science ®Google Scholar
• Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from diuretic optimization strategy evaluation in acute decompensated heart failure (DOSE-AHF) and cardiorenal rescue study in acute decompensated heart failure (CARESS-HF). Circ Heart Fail. 2015;8:741–748.
   PubMed Web of Science ®Google Scholar
• Kociol RD, McNulty SE, Hernandez AF, et al. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail. 2013;6:240–245.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, RC S, AF H, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
   PubMed Web of Science ®Google Scholar
• Packer M, O’Connor C, McMurray JJ, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376:1956–1964.
   PubMed Web of Science ®Google Scholar
• François K, Ronco C, Bargman JM. Peritoneal dialysis for chronic congestive heart failure. Blood Purif. 2015;40:45–52.
   PubMed Web of Science ®Google Scholar
• Courivaud C, Kazory A. Can we treat fluid overload with fluid? Role of peritoneal dialysis in management of heart failure. Eur J Heart Fail. 2012;14:461–463.
   PubMed Web of Science ®Google Scholar
• Adams KF Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005;149:209–216.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr., et al. Efficacy of vasopressin antagonism in heart failure outcome study with Tolvaptan (EVEREST) Investigators: effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319–1331.
   PubMed Web of Science ®Google Scholar
• Bart BA. Treatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ Heart Fail. 2009;2:499–504.
   PubMed Web of Science ®Google Scholar
• Ali SS, Olinger CC, Sobotka PA, et al. Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail. 2009;15(1):1–4.
   PubMedGoogle Scholar
• Rodríguez-Carmona A, Fontán MP. Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int. 2002;22:705–713.
   PubMed Web of Science ®Google Scholar
• Borrelli S, La Milia V, De Nicola L, et al. Sodium removal by peritoneal dialysis: a systematic review and meta-analysis. J Nephrol. 2019;32:231–239.
   PubMed Web of Science ®Google Scholar
• KazoryA, KoratalaA, RoncoC. Customization of peritoneal dialysis in cardiorenal syndrome by optimization of sodium extraction. Cardiorenal Med. 2019;9:117–124.
   PubMed Web of Science ®Google Scholar
• Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int. 1996;50:979–986.
   PubMed Web of Science ®Google Scholar
• Agar BU, Sloand JA. Single daily icodextrin exchange as initial and solitary therapy. Perit Dial Int. 2018;38:119–124.
   PubMed Web of Science ®Google Scholar
• Sánchez JE, Ortega T, Rodríguez C, et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant. 2010;25:605–610.
   PubMed Web of Science ®Google Scholar
• Wojtaszek E1, Grzejszczak A1, Niemczyk S, et al. Peritoneal ultrafiltration in the long-term treatment of chronic heart failure refractory to pharmacological therapy. Front Physiol. 2019;10:310.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure.N. Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Michel A, Martín-Pérez M, Ruigómez A, et al. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail. 2015;17:205–213.
   PubMed Web of Science ®Google Scholar
• Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a Danish population-based cohort study. J Am Heart Assoc. 2018;7:ii: e008912.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Dobre D, McMurray J, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF). JCirc Heart Fail. 2014;7:51–58.
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation. 1999;100:2312–2318.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–1848.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–551.
   PubMed Web of Science ®Google Scholar
• Lopes RJ, Lourenço AP, Mascarenhas J, et al. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol. 2008;31:509–513.
   PubMed Web of Science ®Google Scholar
• Roth GA, Poole JE, Zaha R, et al. Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation. J Am Coll Cardiol. 2016;67:1062–1069.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173–1184.
   PubMed Web of Science ®Google Scholar
• Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212–20.
   PubMed Web of Science ®Google Scholar
• Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;302:1658–1665.
   PubMed Web of Science ®Google Scholar
• Zanger R. Hyponatremia and hypokalemia in patients on peritoneal dialysis. Semin Dial. 2010;23:575–580.
   PubMed Web of Science ®Google Scholar
• Ribeiro SC, Figueiredo AE, Barretti P, et al. Impact of renin-angiotensin aldosterone system inhibition on serum potassium levels among peritoneal dialysis patients. Am J Nephrol. 2017;46:150–155.
   PubMed Web of Science ®Google Scholar
• Cairns KB, Porter GA, Kloster FE, et al. Clinical and hemodynamic results of peritoneal dialysis for severe cardiac failure. Am Heart J. 1968;76:227–234.
   PubMed Web of Science ®Google Scholar
• Chopra MP, Gulati RB, Portal RW, et al. Peritoneal dialysis for pulmonary oedema after acute myocardial infarction. Br Med J. 1970;3:77–80.
   PubMedGoogle Scholar
• McKinnie JJ, Bourgeois RJ, Husserl FE. Long-term therapy for heart failure with continuous ambulatory peritoneal dialysis. Arch Intern Med. 1985;145:1128–1129.
   PubMedGoogle Scholar
• Rubin J, Ball R. Continuous ambulatory peritoneal dialysis as treatment of severe congestive heart failure in the face of chronic renal failure. Report of eight cases. Arch Intern Med. 1986;146:1533–1535.
   PubMedGoogle Scholar
• Tormey V, Conlon PJ, Farrell J, et al. Long-term successful management of refractory congestive cardiac failure by intermittent ambulatory peritoneal ultrafiltration. JQJM. 1996;89:681–683.
   Google Scholar
• Kazory A. Peritoneal dialysis for chronic cardiorenal syndrome: lessons learned from ultrafiltration trials. World J Cardiol. 2015;7:392–396.
   PubMed Web of Science ®Google Scholar
• Kazory A. Fluid overload as a major target in management of cardiorenal syndrome: implications for the practice of peritoneal dialysis. World J Nephrol. 2017;6:168–175.
   PubMedGoogle Scholar
• Koch M, Haastert B, Kohnle M, et al. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail. 2012;14:530–539.
   PubMed Web of Science ®Google Scholar
• Courivaud C, Kazory A, Crépin T, et al. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int. 2014;34:100–108.
   PubMed Web of Science ®Google Scholar
• Pavo N, Yarragudi R, Puttinger H, et al. Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction. PLoS One. 2018;13:e0206830.
   PubMed Web of Science ®Google Scholar
• Cnossen TT, Kooman JP, Krepel HP, et al. Prospective study on clinical effects of renal replacement therapy in treatment-resistant congestive heart failure. Nephrol Dial Transplant. 2012;27:2794–2799.
   PubMed Web of Science ®Google Scholar
• Núñez J, González M, Miñana G, et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail. 2012;14(5):540–548.
   PubMed Web of Science ®Google Scholar
• Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the heart failure association of the European society of cardiology. Eur J Heart Fail. 2018;20:1505–1535.
   PubMed Web of Science ®Google Scholar
• Hedau S, Chakravarthi R, Reddy V. Ultrafiltration by peritoneal route in refractory chronic congestive cardiac failure. Indian J Nephrol. 2018;28:298–302.
   PubMed Web of Science ®Google Scholar
• Kunin M, Carmon V, Arad M, et al. Inflammatory biomarkers in refractory congestive heart failure patients treated with peritoneal dialysis. Biomed Res Int. 2015;2015:590851.
   PubMedGoogle Scholar
• Grossekettler L, Schmack B, Meyer K, et al. Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail. 2019;6:271–279.
   PubMed Web of Science ®Google Scholar
• Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004;10:460–466.
   PubMed Web of Science ®Google Scholar
• Jovanovich A, Ix JH, Gottdiener J, et al. Fibroblast growth factor 23, left ventricular mass and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis. 2013;231:114–119.
   PubMed Web of Science ®Google Scholar
• Hao H, Li X, Li Q, et al. Fgf23 promotes myocardial fibrosis in mice through activation of beta-catenin. Oncotarget. 2016;7:64649–64664.
   PubMedGoogle Scholar
• Verkaik M, Oranje M, Abdurrachim D, et al. High fibroblast growth factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes. Physiol Rep. 2018;6:e13591.
   PubMed Web of Science ®Google Scholar
• Núñez J, González M, Miñana G, et al. Continuous ambulatory peritoneal dialysis and clinical outcomes in patients with refractory congestive heart failure. Rev Esp Cardiol (Engl Ed). 2012;65:986–995.
   PubMed Web of Science ®Google Scholar
• Ross EA. Congestive renal failure: the pathophysiology and treatment of renal venous hypertension. J Card Fail. 2012;18:930–938.
   PubMed Web of Science ®Google Scholar
• Al-Hwiesh AK. Percutaneous peritoneal dialysis catheter insertion by a nephrologist: a new, simple, and safe technique. Perit Dial Int. 2014;34:204–211.
   PubMed Web of Science ®Google Scholar
• Sandrini M, Vizzardi V, Valerio F. Incremental peritoneal dialysis: a 10 year single-centre experience. J Nephrol. 2016;29:871–879.
   PubMed Web of Science ®Google Scholar
• Bertoli SV, Musetti C, Ciurlino D, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int. 2014;34:64–70.
   PubMed Web of Science ®Google Scholar
• Guglielmi AA, Guglielmi KE. Peritoneal dialysis after left ventricular assist device placement. Asaio J. 2014;60:127–128.
   PubMed Web of Science ®Google Scholar
• Thomas BA, Logar CM, Anderson AE. Renal replacement therapy in congestive heart failure requiring left ventricular assist device augmentation. Perit Dial Int. 2012;32:386–392.
   PubMed Web of Science ®Google Scholar
• Ponce D, Góes C, Oliveira M, et al. Peritoneal dialysis for the treatment of cardiorenal syndrome Type 1: a prospective Brazilian Study. Perit Dial Int. 2017;37:578–583.
   PubMed Web of Science ®Google Scholar
• Fitch K, Engel T, Lau J The cost burden of worsening heart failure in the medicare fee for service population: an actuarial analysis. 2017. [cited 2018 Apr 29]. Available from: http://us.milliman.com/uploadedFiles/insight/2017/cost-bruden-worsening-heart-failure.pdf
   Google Scholar